Trials / Completed
CompletedNCT00103350
Safety of TG100-115 for Heart Attack Treated With Angioplasty
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Prospective Study to Evaluate the Safety and Potential Efficacy of Single, Increasing Doses of TG100-115 in Subjects Undergoing Percutaneous Coronary Intervention for Acute Anterior ST Elevation Myocardial Infarction
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- TargeGen · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis of this study is that TG100-115 can be given safely to patients who suffer a heart attack and undergo angioplasty to restore blood flow. We will also evaluate whether TG100-115 reduces heart muscle damage.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TG100-115 |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2006-12-01
- Completion
- 2008-01-01
- First posted
- 2005-02-08
- Last updated
- 2008-05-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00103350. Inclusion in this directory is not an endorsement.